VCI Wealth Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD

VCI Wealth Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 15,683 shares of the biopharmaceutical company’s stock, valued at approximately $2,186,000.

Several other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares during the period. State Street Corp increased its position in shares of Gilead Sciences by 1.9% during the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after purchasing an additional 1,151,213 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Gilead Sciences by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after purchasing an additional 1,195,269 shares during the period. Bank of America Corp DE raised its stake in shares of Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after purchasing an additional 3,046,688 shares during the period. Finally, Norges Bank purchased a new position in shares of Gilead Sciences in the 4th quarter worth about $2,617,152,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $127.86 on Friday. The firm has a market capitalization of $158.75 billion, a P/E ratio of 17.42 and a beta of 0.31. Gilead Sciences, Inc. has a one year low of $106.84 and a one year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The business has a fifty day moving average price of $130.19 and a 200-day moving average price of $134.28.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the sale, the chief executive officer directly owned 617,567 shares in the company, valued at $81,185,357.82. This trade represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock worth $8,930,150 over the last ninety days. Company insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on GILD shares. Truist Financial restated a “buy” rating and set a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Citigroup upped their price objective on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Daiwa Securities Group reduced their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Rothschild & Co Redburn lowered their target price on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Finally, Morgan Stanley dropped their price target on Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $158.41.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Trodelvy won first-line approval in the U.S. and Europe for metastatic triple-negative breast cancer, opening a larger treatment market and improving Gilead’s oncology growth profile. Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
• Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and $155 price target after positive HIV trial results, signaling continued analyst confidence in Gilead’s pipeline and longer-term earnings potential. Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results
• Positive Sentiment: Merck’s FDA announcement that KEYTRUDA combinations can be used with Trodelvy in first-line advanced TNBC adds another validation point for Trodelvy’s role in frontline cancer care. FDA Approves KEYTRUDA and KEYTRUDA QLEX each with Trodelvy as First-Line Treatment of Advanced Triple-Negative Breast Cancer
• Neutral Sentiment: Recent coverage also noted Gilead’s stock had been drifting lower before the approval news, reflecting recent market weakness rather than a change in fundamentals. Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.